CN107970240B - Application of RamosisimoneB in preparation of medicine for treating rheumatoid arthritis - Google Patents
Application of RamosisimoneB in preparation of medicine for treating rheumatoid arthritis Download PDFInfo
- Publication number
- CN107970240B CN107970240B CN201810043909.3A CN201810043909A CN107970240B CN 107970240 B CN107970240 B CN 107970240B CN 201810043909 A CN201810043909 A CN 201810043909A CN 107970240 B CN107970240 B CN 107970240B
- Authority
- CN
- China
- Prior art keywords
- rheumatoid arthritis
- synovial cells
- application
- ramosissimone
- proliferation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention relates to application of a compound Ramosissimoe B in preparing a medicament for treating rheumatoid arthritis. Pharmacological experiments prove that ramosissimone B has obvious activities of inhibiting the proliferation of rheumatoid arthritis synovial cells and inducing the apoptosis of the rheumatoid arthritis synovial cells for the first time, and can be used for preparing medicines for preventing and/or treating rheumatoid arthritis, so that the ramosissimone B has higher clinical application value and development prospect. The invention discloses application of a compound ramosisimone B in preparation of a medicine for resisting rheumatoid arthritis. The structural formula of Ramosissimoe B is shown as a formula I, and the Ramosissimoe B is obtained by separating from branches of the multi-branch tamarisk. The invention discovers for the first time that ramosissimone B can obviously inhibit the proliferation of rheumatoid arthritis synovial cells and induce the apoptosis of the rheumatoid arthritis synovial cells.
Description
Technical Field
The invention relates to application of a compound RamosisimoneB in preparing a medicament for treating rheumatoid arthritis.
Background
Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease mainly characterized by arthropathy, the pathogenesis of which is unknown at present, and the clinical thinking that the pathogenesis of RA is mainly caused by allergic reaction due to autoimmune dysfunction of patients, so that anti-inflammatory cells deteriorate and denature and deposit in joint parts and joint tissues are deformed and disabled. According to investigation, the incidence rate of RA in the world is about 1-2%, the total number of RA patients in China is over 400 ten thousand, and the incidence rate is still on the rise.
At present, non-steroidal anti-inflammatory drugs (diclofenac, aspirin and the like) and immunosuppressants (6-mercaptopurine and the like) are mainly used for treating rheumatoid arthritis, but the drugs have obvious adverse reactions, such as peptic ulcer caused by the fact that the former damages gastrointestinal mucosa, and infection is easily induced by the latter. Therefore, research and development of safe and effective drugs for treating rheumatoid arthritis is an urgent task at present.
In recent years, scholars at home and abroad make extensive and intensive research on the aspect of treating RA by using plant medicines, and discover that a plurality of natural medicines such as erycibe glycoside, total glucosides of paeony, poison vine and the like have better RA treatment effect. Therefore, the safe and efficient RA treatment medicine has wide prospect from the botanical medicine.
Disclosure of Invention
The invention aims to provide application of a compound Ramosissimone B in preparing a medicament for treating rheumatoid arthritis, which has remarkable activities of inhibiting the proliferation of rheumatoid arthritis synovial cells and inducing the apoptosis of the rheumatoid arthritis synovial cells and can be used for preparing the medicament for preventing and/or treating the rheumatoid arthritis.
The application of Ramosisssimone B in preparing a medicament for preventing or treating rheumatoid arthritis, wherein the structural formula of the compound Ramosisssimone B is as follows:
the application of Ramosisssimone B in preparing a medicament for inhibiting the proliferation of rheumatoid arthritis synovial cells, wherein the structural formula of the compound Ramosisssimone B is as follows:
pharmacological experiments prove that ramosissimone B has obvious activities of inhibiting the proliferation of rheumatoid arthritis synovial cells and inducing the apoptosis of the rheumatoid arthritis synovial cells for the first time, and can be used for preparing medicines for preventing and/or treating rheumatoid arthritis, so that the ramosissimone B has higher clinical application value and development prospect.
The invention discloses application of a compound ramosisimone B in preparation of a medicine for resisting rheumatoid arthritis. The structural formula of Ramosissimoe B is shown as a formula I, and the Ramosissimoe B is obtained by separating from branches of the multi-branch tamarisk. The invention discovers for the first time that ramosissimone B can obviously inhibit the proliferation of rheumatoid arthritis synovial cells and induce the apoptosis of the rheumatoid arthritis synovial cells. Therefore, the compound can be used for preparing a medicament for preventing and/or treating rheumatoid arthritis, and has higher clinical application value and development prospect.
Drawings
FIG. 1 is a graph showing the statistical results of inhibition of proliferation of synovial cells in rheumatoid arthritis by ramosissimone B at various concentrations in example 1 of the present invention;
FIG. 2 is a graph showing the statistical results of the promotion of apoptosis in rheumatoid arthritis synovial cells by ramosissimone B at various concentrations in example 2 of the present invention.
Detailed Description
The invention aims to provide application of a compound ramosisimone B in inhibition of proliferation of synovial cells of rheumatoid arthritis and prevention and/or treatment of rheumatoid arthritis.
The structural formula of the compound ramosisimone B related by the invention is shown as a formula I:
the compound is obtained by separating from Tamarix ramosissima Ledeb (Zingiberaceae. Salix purpurea chemical composition research [ D ]. Ningxia medical university, 2016). The multi-branch tamarix chinensis is an excellent tree species for wind-proof sand-fixation plants and saline-alkali land afforestation, and is widely distributed in northwest areas of China and rich in resources.
The application of ramosissimone B provided by the invention comprises two aspects: 1) the application of the compound in preparing products for preventing and/or treating rheumatoid arthritis; 2) the application of the compound in preparing products for inhibiting the proliferation of rheumatoid arthritis synovial cells.
The preparation method is specifically shown in that ramosissimone B can obviously inhibit the proliferation of rheumatoid arthritis synovial cells and induce the apoptosis of the rheumatoid arthritis synovial cells, and can be used for preparing medicines for preventing and/or treating rheumatoid arthritis.
In addition, the following products were prepared with ramosisimone B as an active ingredient: 1) products for the prevention and/or treatment of rheumatoid arthritis; 2) the product for inhibiting the proliferation of synovial cells in rheumatoid arthritis also belongs to the protection scope of the invention.
The agent for preventing and/or treating rheumatoid arthritis and the agent for inhibiting proliferation of synovial cells of rheumatoid arthritis in the present invention can be introduced into the body such as muscular, intradermal, subcutaneous, intravenous, mucosal tissue by injection, permeation, absorption, physical or chemical-mediated method; or mixed or coated with other materials and introduced into body.
If necessary, one or more pharmaceutically acceptable carriers can be added into the medicine. The carrier includes diluent, excipient, filler, binder, wetting agent, disintegrating agent, absorption enhancer, surfactant, adsorption carrier, lubricant, etc. which are conventional in the pharmaceutical field.
The above medicine can be made into various forms such as injection, tablet, powder, granule, capsule, oral liquid, paste, cream, etc. The medicines in the above various dosage forms can be prepared according to the conventional method in the pharmaceutical field.
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Example 1:
the Ramosissimoe B has the effect of inhibiting the proliferation of synovial cells of rheumatoid arthritis.
Cell: human rheumatoid arthritis synovial cells (RA-FLS);
medicine preparation: ramosisimone B;
the method comprises the following steps: resuscitation of RA-FLS
And (3) quickly taking out the RA-FLS cryopreservation tube from the liquid nitrogen tank, putting the RA-FLS cryopreservation tube into a constant-temperature water bath kettle with the temperature of 37 ℃, and continuously shaking to accelerate cell thawing. After the thawing is completed, the water is placed in a super clean benchAnd transferring the RA-FLS suspension in the freezing tube into a 10mL sterile centrifuge tube by using a pipette, and centrifuging for 5min at the rotating speed of 1000 r/min. Pouring out supernatant, adding 5mL of complete culture solution, continuously blowing to obtain uniform cell suspension by using a pipette, inoculating RA-FLS into a 25mL cell culture bottle, and culturing in a cell culture box with the conditions of 37 ℃ and CO2The concentration was 5%. After 24h, the growth of RA-FLS is observed under a microscope, and when the cells are attached to the wall, are triangular and irregularly fusiform, the cell growth is good.
Passage of RA-FLS
When the RA-FLS grows to be about 80 percent of the bottom of the whole cell culture bottle by adherence under a microscope, cell passage can be carried out. Pouring out the original culture solution in the culture bottle, and washing with PBS for 2 times, so as to clean the original culture solution and avoid affecting cell digestion; adding 0.25% trypsin digestive juice for digestion, observing the digestion condition of RA-FLS under a microscope, adding a proper amount of Fetal Bovine Serum (FBS) to stop digestion when most cells are rounded under the microscope, then adding a certain amount of complete culture solution into a culture bottle, and repeatedly blowing the inner wall of the culture bottle by using a sterile pipette to form uniform cell suspension; counting the cells with a cell counting plate, inoculating RA-FLS into 2 new culture bottles after counting, adding appropriate amount of complete culture solution, culturing in a cell culture box with the temperature of 37 ℃ and CO2The concentration is 5%, i.e. subculture in a one-to-two manner.
Determination of cell inhibition Rate by MTT method
Taking a proper amount of ramosisimone B, preparing culture solution with the concentration of 0.01, 0.1, 1, 5 and 10 mu M by DMEM respectively, taking RA-FLS in logarithmic phase, pouring out original culture solution in a culture bottle, washing for 2 times by PBS, adding 0.25% trypsin digestive juice for digestion, observing the digestion condition of RA-FLS under a microscope, adding a proper amount of FBS to stop digestion when most cells are rounded under a microscope, adding a certain amount of culture solution into the culture bottle, continuously blowing the inner wall of the culture bottle by a sterile pipette to form uniform cell suspension, counting by a cell counting plate, regulating the cell concentration to be 1 × 10 by using the culture solution, and then adding a certain amount of culture solution into the culture bottle5Inoculating RA-FLS into 96-well sterile cell culture plate (100 μ L per well), culturing in cell culture box (temperature 37 deg.C, CO)2The concentration was 5%. After 24h incubation, the 96-well plate is divided into 6 groups (namely blank control group, 0.01, 0.1, 1, 5 and 10 mu M drug group, each group has 6 multiple wells), the stock culture solution in the wells is sucked, the same amount of DMEM and the drug-containing culture medium with different concentrations are respectively added, and the mixture is put into a cell incubator for intervention. After intervention for 24h and 48h, 20 μ L of MTS was added to each well, incubated at 37 ℃ for 1.5h, and the absorbance of each well at a wavelength of 540nm was measured with an enzyme linked immunosorbent assay to calculate the inhibition rate of each group of cells.
The calculation formula is as follows:
the cell inhibition rate/% (1-blank control group OD value/each concentration drug group OD value) × 100%
As a result: the ramosissimone B with the concentration of 0.1-10 mu M can obviously inhibit the proliferation of RA-FLS, and the inhibition effect is enhanced along with the increase of the drug concentration.
Example 2:
promoting Ramosissimoe B to the apoptosis of rheumatoid arthritis synovial cells.
Cell: human rheumatoid arthritis synovial cells (RA-FLS);
medicine preparation: ramosisimone B;
the method comprises the following steps: resuscitation of RA-FLS
Same as in example 1.
Passage of RA-FLS
Same as in example 1.
Determination of apoptosis by TUNEL method
The fragmentation of chromosomal DNA during apoptosis is a gradual, staged process, with chromosomal DNA first being degraded into large fragments of 50-300kb by endogenous nucleolytic enzymes. Then about 30% of the chromosomal DNA is in Ca2+And Mg2+Under the action of the dependent endonuclease, nucleosome units are cut off randomly to form a nucleosome DNA polymer of 180-200 bp. The 3' -OH end of a DNA double strand break or a series of DNAs produced by nicking only one strand can be converted at the deoxyribonucleotide endDetection of apoptotic cells can be carried out by labeling the 3' -end of DNA with a derivative of deoxyribonucleotide and fluorescein, peroxidase, alkaline phosphorylase or biotin by the action of transferase (TdT), which is generally referred to as deoxyribonucleotide terminal transferase-mediated nick terminal labeling (TUNEL).
A proper amount of ramosisimone B is prepared into culture solutions of 0.1 mu M and 1 mu M respectively by DMEM, RA-FLS cells are incubated in a blank and drug-containing culture solution for 48h, and fixed by 4% paraformaldehyde for 30min at room temperature. Rinsing with Phosphate Buffer Solution (PBS) for 3 times, adding cell membrane permeation solution (0.1% sodium citrate, 0.1% TritonX-100) and acting for 2 min. The labeling reaction was carried out at 37 ℃ for 1h using deoxyribonucleotide terminal transferase (TdT) and biotin-11-deoxyuridine triphosphate (biotin-11-dUTP). Cell morphology was observed using a fluorescence microscope and apoptosis index was calculated.
The calculation formula is as follows:
apoptosis index/% (number of apoptotic cells/1000 in 1000 cells) × 100%.
In the application of the RamosissimeB in preparing the medicine for treating rheumatoid arthritis, the dosage of the RamosissimeB is 0.2-1.0 mg/kg/day, and the RamosissimeB is orally taken.
Claims (2)
- Use of Ramosissimone B as the sole active ingredient for the preparation of a medicament for the prevention or treatment of rheumatoid arthritis, wherein the compound ramosimone B has the following structural formula:
- the use of ramosisimone B as the sole active ingredient in the manufacture of a medicament for inhibiting the proliferation of rheumatoid arthritis synovial cells, wherein the compound ramosisimone B has the following structural formula:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810043909.3A CN107970240B (en) | 2018-01-17 | 2018-01-17 | Application of RamosisimoneB in preparation of medicine for treating rheumatoid arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810043909.3A CN107970240B (en) | 2018-01-17 | 2018-01-17 | Application of RamosisimoneB in preparation of medicine for treating rheumatoid arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107970240A CN107970240A (en) | 2018-05-01 |
| CN107970240B true CN107970240B (en) | 2020-10-09 |
Family
ID=62006017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810043909.3A Active CN107970240B (en) | 2018-01-17 | 2018-01-17 | Application of RamosisimoneB in preparation of medicine for treating rheumatoid arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107970240B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581092A (en) * | 2016-11-28 | 2017-04-26 | 宁夏医科大学 | Tamarix ramosissima Ledeb extract and application thereof in preparation of medicine for treatment of rheumatoid arthritis |
-
2018
- 2018-01-17 CN CN201810043909.3A patent/CN107970240B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| Fischer indolisation of N-(α-ketoacyl)anthranilic acids into 2-(indol-2-carboxamido)benzoic acids and 2-indolyl-3,1-benzoxazin-4-ones and their NMR study;Karel Proisl, et al.;《Org. Biomol. Chem.》;20141231(第12期);9650–9664 * |
| Oxidative ring opening of 3-hydroxyquinoline-2,4(1H,3H)-diones into N-(a-ketoacyl)anthranilic acids;Stanislav Kafka, et al.;《Tetrahedron》;20131101;第69卷;10826-10835 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107970240A (en) | 2018-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107970240B (en) | Application of RamosisimoneB in preparation of medicine for treating rheumatoid arthritis | |
| CN108186625B (en) | Application of RamosisimoneA in preparing medicine for treating rheumatoid arthritis | |
| CN107961234B (en) | Application of Ramosissimarin in preparation of medicine for treating rheumatoid arthritis | |
| CN108272789B (en) | Application of Ramosissimin in preparation of medicine for treating rheumatoid arthritis | |
| CN109846870A (en) | Phenolic acid compound is preparing the purposes in resisting rheumatoid arthritis drug | |
| CN112891363B (en) | New Zealand vitexin 2 and new Zealand vitexin 3 application | |
| JPH0930981A (en) | Immunopotentiative composition | |
| CN112516183B (en) | Preparation method and application of extract with repair effect on trauma | |
| CN110327317B (en) | Application of alkannin in preparing medicine for resisting rotavirus infection | |
| CN112891360A (en) | New application of deoxyrhaponticin | |
| CN106491589A (en) | Applications of the Linderolide H in treatment acute gout medicine is prepared | |
| CN102068479B (en) | Chinese medicinal composition for treating chronic urinary tract infection and preparation method thereof | |
| CN111345419A (en) | Compound fermentation type shark cartilage powder health drink | |
| CN111920833A (en) | Application of fermentation liquor of phyllobacterium ribrum in preparation of medicine for treating immune factor storm | |
| CN101011567A (en) | Medicament for treating AIDS and its preparing method | |
| CN109925306A (en) | Syringaresinol is preparing the purposes in resisting rheumatoid arthritis drug | |
| AU2020103248A4 (en) | The preparation and application of antifungal extracts from Oxytropis falcate Bunge | |
| CN1279953A (en) | Application of seeweed polyose sulphate | |
| CN1128622C (en) | Medicinal composition for treating AlDS | |
| CN117017976A (en) | Application of thapsigargin in preparation of medicines for resisting porcine hemagglutinating encephalomyelitis virus infection | |
| CN100344747C (en) | Sulfated NF1 granulose-anti-AIDS medicine and its preparing method | |
| CN112274528A (en) | Application of marine bacillus exopolysaccharide in preparation of anti-inflammatory drugs | |
| TW202220680A (en) | A composition for angiogenesis inhibition and its use | |
| CN105250266A (en) | Application of Hirsutellone B in preparing medicine for curing acute gout | |
| CN112933074A (en) | New application of cynarin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |